EUVIMEDEUVIMED entdecken
Crossref

Blockage of CCL3 with neutralizing antibody reduces neuroinflammation and reverses Alzheimer disease phenotypes

Chao Wei, Jing Liu, Bing Wu, Tianhao Shen, Jiao Fan, Ye Lin, Ke Li, Yane Guo, Yanchang Shang, Bo Zhou, Hengge Xie

Brain, Behavior, and Immunity · 2025-08 · 128 · 400-415

DOI: 10.1016/j.bbi.2025.04.034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, Behavior, and Immunity, 2025-08. Verfasst von Chao Wei und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, the Second Medical Center and National Clinical Research Center of Geriatric Diseases, Chinese PLA General Hospital, Beijing…. Hauptthemen laut MEDLINE: Alzheimer Disease, Chemokine CCL3, Antibodies, Neutralizing, Neuroinflammatory Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Key Technologies Research and Development Program, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Accumulating evidence indicates that neuroinflammation is involved in the pathogenesis of Alzheimer's disease (AD). According to RNA sequencing and quantitative PCR (qPCR), we found that chemokine CCL3 mRNA expression was abnormally upregulated in the brains of AD transgenic mice. Moreover, the levels of CCL3 in the serum of AD patients were significantly elevated and negatively correlated with their cognitive abilities. However, the role of CCL3 in AD neuroinflammation and pathological damages remains elusive. METHODS: Using behavioral, histological, and biochemical methods, outcomes of CCL3 antibody treatment on neuropathology and cognitive deficits were studied in the APPswe/PS1dE9 mice. RESULTS: In the present study, we reported that CCL3 protein expression was increased in the APPswe/PS1dE9 mice, whereas blockage of CCL3 with neutralizing antibody potently inhibited CCL3 activation in the APPswe/PS1dE9 mice down to the levels of wild-type mice. Specifically, CCL3 antibody significantly improved the learning and memory abilities of APPswe/PS1dE9 mice. In addition, CCL3 antibody treatment decreased cerebral amyloid-β (Aβ) levels and plaque burden via inhibiting amyloid precursor protein (APP) processing by reducing beta-site APP cleaving enzyme 1 (BACE1) expression in the APPswe/PS1dE9 mice. We also found that CCL3 antibody treatment alleviated neuroinflammation and reduced synaptic defects in the APPswe/PS1dE9 mice. Furthermore, the activated NF-κB signaling pathway in APPswe/PS1dE9 mice was inhibited by CCL3 antibody treatment. CONCLUSIONS: Collectively, our findings provide evidence that CCL3 activation may contribute to the AD pathogenesis and may serve as a novel therapeutic target in the treatment of AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseChemokine CCL3Antibodies, NeutralizingNeuroinflammatory DiseasesAnimalsMiceMice, TransgenicAmyloid beta-PeptidesHumansMaleBrainDisease Models, AnimalAmyloid Precursor Protein SecretasesInflammationFemalePhenotypeMice, Inbred C57BLAmyloid beta-Protein Precursor

Stichwörter der Autor:innen

Alzheimer’s diseaseAmyloid-β peptideCCL3Cognitive dysfunctionNeuroinflammation

Substanzen

Chemokine CCL3Antibodies, NeutralizingAmyloid beta-PeptidesCcl3 protein, mouseAmyloid Precursor Protein SecretasesAmyloid beta-Protein Precursor

Autor:innen und Institutionen

  • Department of Neurology, the Second Medical Center and National Clinical Research Center of Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China. Electronic address: weichao301@163.com.cn.
  • Institute of Geriatrics, the Second Medical Center and National Clinical Research Center of Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China.
  • Department of Geriatrics, the 940th Hospital of Joint Logistics Support Force of PLA, Lanzhou 730050, China.
  • Peking University Health Science Center, Beijing 100191, China.
  • Department of Neurology, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
  • Department of Neurology, the Second Medical Center and National Clinical Research Center of Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China.

Förderung

  • Key Technologies Research and Development Program
  • National Natural Science Foundation of China

Zitieren

APA

Wei, C., Liu, J., Wu, B., Shen, T., Fan, J., Lin, Y., Li, K., Guo, Y., Shang, Y., Zhou, B., & Xie, H. (2025). Blockage of CCL3 with neutralizing antibody reduces neuroinflammation and reverses Alzheimer disease phenotypes. Brain, Behavior, and Immunity, 128, 400-415. https://doi.org/10.1016/j.bbi.2025.04.034

Vancouver

Wei C, Liu J, Wu B, Shen T, Fan J, Lin Y, et al. Blockage of CCL3 with neutralizing antibody reduces neuroinflammation and reverses Alzheimer disease phenotypes. Brain, Behavior, and Immunity. 2025;128:400-415. doi:10.1016/j.bbi.2025.04.034

BibTeX
@article{Wei2025,
  author = {Wei, Chao and Liu, Jing and Wu, Bing and Shen, Tianhao and Fan, Jiao and Lin, Ye and Li, Ke and Guo, Yane and Shang, Yanchang and Zhou, Bo and Xie, Hengge},
  title = {Blockage of CCL3 with neutralizing antibody reduces neuroinflammation and reverses Alzheimer disease phenotypes},
  journal = {Brain, Behavior, and Immunity},
  year = {2025},
  volume = {128},
  pages = {400--415},
  doi = {10.1016/j.bbi.2025.04.034}
}
Kostenlos starten →